


0300

8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Eisinger, et al.
SERIAL NO: 09/653,755
FILED: September 1, 2000
FOR: A Recombinant Monoclonal Antibody to Phosphotyrosine-Containing Proteins
DOCKET NO: 724650-3



Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

 §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- The statement as specified in 37 CFR §1.97(e) set out below;
OR
 The fee of \$240.00 under 37 CFR §1.17(p).

___§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).



___§1.97(e) The undersigned Attorney hereby states that:

___ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

___ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

<p>FIRST CLASS CERTIFICATE</p> <p>I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to: Box Patent Application Assistant Comm. for Patents Washington, D.C. 20231</p> <p> Alan J. Grant, Esq. Date <u>11/17/01</u></p>	<p>Respectfully submitted,</p> <p> Alan J. Grant, Esq. Reg. No. 33,389 CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN Six Becker Farm Road Roseland, NJ 07068 Tel: (973)994-1700 Fax: (973)994-1744</p>
--	--

Form PTO-1449

INFORMATION DISCLOSURE STATEMENTAtty. Docket:
724650-3Serial No.:
09/653,755

Applicant: Eisinger et al.

Filing Date: September 1, 2000

Group:

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1						
	B1						
	C1						
	D1						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	N1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	O1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	P1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	Q1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	R1						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	S1	Flier, et al., "Oncogenes, Growth Factors, and Signal Transduction," Seminars in Medicine of the Beth Israel Hospital, Vol. 321, No. 20, pp. 1383-1391 (Nov. 1989).
	T1	Kanakura, et al., "Signal Transduction of the Human Granulocyte-Macrophage Colony-Stimulating ...," Blood, Vol. 76, No. 4, pp. 706-715 (August 15).
	U1	Morrison, et al., "Tyrosine Phosphorylations In Vivo Associated with <i>v-fms</i> Transformation," Molecular and Cellular Biology, pp. 176-185 (January 1988).
	V1	Ward, et al., "Regulation of Phosphoinositide Kinases in T Cells," The Journal of Biological Chemistry, Vol. 267, No. 33, pp. 23862-23869 (November 1992).
	W1	Cohen, et al., "Tyrosine phosphorylation is a signal for the Trafficking of pp85, an 85-kDa phosphorylated polypeptide associated with phosphatidylinositol kinase activity," Proc. Nat'l. Acad. Sci., Vol. 87, pp. 4458-4462 (June 1990).
	X1	
	Y1	
	Z1	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.